GEN Roundup: Multiplexed Immunoassays: Small Samples, Big Pictures
Taking in "Everything All at Once" Can Reveal Meaningful Biological Patterns and Drug Targets
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
For full access to this article login to GEN Select now.
Exceptional Responders: The “N of 1” Paradigm
Hope for Better Cancer Treatments May Lie in Those Patients Who Respond Exceptionally Well
- We have all heard stories about the single patient who survives a deadly cancer in response to a particular drug, in contrast to other patients receiving the same drug who succumb to the disease. These patients may include heavily pretreated cancer patients for whom other drugs have failed, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.